Xeris Biopharma Files Q1 2025 10-Q
Ticker: XERS · Form: 10-Q · Filed: May 8, 2025 · CIK: 1867096
| Field | Detail |
|---|---|
| Company | Xeris Biopharma Holdings, Inc. (XERS) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biopharma
TL;DR
Xeris Biopharma's Q1 2025 10-Q is in, check financials for latest performance.
AI Summary
Xeris Biopharma Holdings, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025. Specific financial figures and business segment performance are outlined within the report.
Why It Matters
This filing provides investors with the latest financial health and operational status of Xeris Biopharma, crucial for understanding the company's trajectory and investment potential.
Risk Assessment
Risk Level: medium — As a biopharma company, Xeris is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — End of Reporting Period (The 10-Q covers financial data up to this date.)
- 2025-01-01 — Start of Reporting Period (The 10-Q covers financial data from this date.)
- 2024-12-31 — Previous Year End (Comparative financial data may be presented against this date.)
Key Players & Entities
- Xeris Biopharma Holdings, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 20250508 (date) — Filing date
- 1375 WEST FULTON STREET, SUITE 1300 (address) — Company business and mailing address
- CHICAGO (location) — City of company address
- IL (location) — State of company address
- 60607 (postal_code) — Zip code of company address
- 844-445-5704 (phone_number) — Company business phone number
FAQ
What were Xeris Biopharma's total revenues for the first quarter of 2025?
The filing indicates revenue data for the period January 1, 2025 to March 31, 2025, but specific dollar amounts are not provided in this header information.
What is Xeris Biopharma's primary business address?
Xeris Biopharma's business address is 1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL 60607.
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted on May 8, 2025.
What fiscal year end does Xeris Biopharma report?
Xeris Biopharma's fiscal year ends on December 31.
What is the SEC file number for Xeris Biopharma?
The SEC file number for Xeris Biopharma is 001-40880.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Xeris Biopharma Holdings, Inc. (XERS).